An important pathophysiology of Alzheimer’s disease is the accumulation of soluble and insoluble aggregated amyloid-beta (Aβ). Lecanemab, a humanized monoclonal antibody, binds to such soluble Aβ protofibrils with high affinity, and the drug is found to be more toxic to neurons in comparison to monomers or insoluble fibrils. A recent multicenter, double-blind, phase 3 trial has evaluated the safety and efficiency of lecanemab in participants with early Alzheimer’s disease. Published in N Engl J Med, 2022. Authors: Van Dyck CH, Swanson CJ, Aisen P et al. What was the need for the study?
A previous dose-determining 12-month trial did not show much significant difference between lecanemab and placebo. That is why a trial for a larger period of time was conducted to check dose- and time-dependent clearance of amyloid with lecanemab. How was the study conducted? Table 1. Details of the…
